.png){kind=logo}
Whatever respiratory season may bring,
we’re ready
QuidelOrtho has been dedicated to innovating a broad spectrum of respiratory testing solutions for decades. From rapid antigen to molecular, point-of-care to the core lab, we’ve got you covered.
.png)
Rapid lateral-flow tests with a clear visual read window provide accurate results in just minutes. With an easy-to-use platform and expansive test menu, including an array of infectious diseases, women’s health, general health, and at-home diagnostics, you can provide confident answers for faster patient diagnosis and treatment.
​
-
Influenza A+B
-
RSV
-
SARS Antigen*
-
Strep A
Compact and powerful benchtop testing using proven lateral-flow technology and advanced fluorescence chemistry. Accurate and objective results are automatically reported on the easy-to-use touch screen in as few as three minutes.
​
-
Influenza A+B
-
SARS Antigen*
-
SARS Antigen+
-
Strep A+
-
RSV
-
Flu + SARS Antigen*
Put the accuracy of molecular diagnostics at your fingertips. Benchtop testing with capacity to run one to 12 tests at a time, plus proprietary helicase-dependent amplification with fluorescence detection to make diagnosing infectious diseases faster and easier than ever before.
​
-
Influenza A+B
-
RSV + hMPV
-
SARS-CoV-2*
-
Strep Complete
-
GAS
-
Bordetella Complete
For high-volume testing and throughput, Vitros Automated Solutions improve workflow efficiency and increase productivity while helping lab staff stay focused on higher-value tasks. Meticulous planning, lean design, and personalized training and support make implementation easy, leading to quicker turnaround time, improved safety, and less stress and pressure for staff.
​
-
Anti-SARS-CoV-2 Total
-
Anti-SARS-CoV-2 IgG
New QuidelOrtho Vitros System branding may not be available in all markets, subject to country-specific regulatory approval. Please confirm with your local commercial team.
Submit this form to be contacted by a QuidelOrtho representative with more information.
*THESE TESTS ARE AVAILABLE FOR SALE IN THE USA UNDER EMERGENCY USE AUTHORIZATION. These SARS tests have not been cleared or approved by the FDA, but have been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories for the detection of proteins (QuickVue and Sofia) or nucleic acids (Solana) from SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless terminated or revoked sooner.